<html><head></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; ">Sean-<div><br></div><div>MAPS isn't the only organization funding psychedelic research. The Beckley Foundation in the UK, as well as another org in the US (I can't remember the name right now) are some fairly major players.</div><div><br></div><div>MAPS alone is a multi-million dollar non-profit funding dozens of studies around the world, at various institutions (John Hopkins, NYU, etc).</div><div><br></div><div>But I agree there certainly should be more pharmaceutical orgs working on psychedelic science! MAPS has selected MDMA treatment for PTSD because they think it will be their best shot at getting a psychedelic through the clinical trial process. Because MDMA is well out of patent (as many psychedelics are), it means MAPS must take a unique non-profit approach to the drug development. In the next ~10 years, I expect MAPS will succeed at their vision- of getting MDMA through through the trials, opening psychedelic clinics around the world, and becoming leaders in the psychedelic science space. But it doesn't mean other drug companies won't produce "generic" forms of these compounds.</div><div><br></div><div>It's going to be a fascinating time ahead. Psychedelic science has had an amazing resurgence, the biggest modern civilization has seen since the original "discovery" of these compounds by pharmaceutical companies for psychotherapy use in the 60s.</div><div><br><div>
<span class="Apple-style-span" style="border-collapse: separate; color: rgb(0, 0, 0); font-family: Helvetica; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; -webkit-text-decorations-in-effect: none; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; font-size: medium; "><div><div>--</div><div>Daniel Jabbour</div><div>Organizer, Psychedelic Society of San Francisco</div><div><a href="http://www.PsychedelicSF.org">http://www.PsychedelicSF.org</a></div><div><a href="mailto:daniel@psychedelicsf.org">daniel@psychedelicsf.org</a></div></div></span>
</div>
<br><div><div>On Feb 29, 2012, at 12:53 AM, Sean Cusack wrote:</div><br class="Apple-interchange-newline"><blockquote type="cite">Sorry was on my phone and couldn't actually do the search on clinicaltrials...good call!<div><br></div><div>Interestingly enough, a different, but related study has already completed, it is (was) a Phase II trial aimed at PTSD resulting from a crime: <a href="http://clinicaltrials.gov/ct2/show/NCT00090064?term=MDMA&rank=14">http://clinicaltrials.gov/ct2/show/NCT00090064?term=MDMA&rank=14</a></div>
<div><br></div><div>Its got a publication too (non-printed, but digital!), and from the looks of it, 80% of 12 patients on the experimental arm got better...neat! <a href="http://www.ncbi.nlm.nih.gov/pubmed/20643699?dopt=Abstract">http://www.ncbi.nlm.nih.gov/pubmed/20643699?dopt=Abstract</a></div>
<div><br></div><div>Could be pretty interesting...any reason the MAPS guys are trying to go it alone? To launch the drug, someone will need to do the spendy Phase III trial...and it looks like there could be some help from other people(!)</div>
<div><br></div><div>Sean</div><div><br><div class="gmail_quote">On Wed, Feb 29, 2012 at 12:37 AM, Daniel Jabbour <span dir="ltr"><<a href="mailto:daniel@psychedelicsf.org">daniel@psychedelicsf.org</a>></span> wrote:<br>
<blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex"><div style="word-wrap:break-word">Oh, and you're right, the trials are posted on <a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>. Just search for MDMA...<div>
<br></div><div>Here's one for example that's currently recruiting participants:</div><div><a href="http://clinicaltrials.gov/ct2/show/NCT01211405?term=MDMA&rank=8" target="_blank">http://clinicaltrials.gov/ct2/show/NCT01211405?term=MDMA&rank=8</a></div>
<div><br></div><div><div class="im"><div>
<div><div>--</div><div>Daniel Jabbour</div><div>Organizer, Psychedelic Society of San Francisco</div><div><a href="http://www.PsychedelicSF.org/" target="_blank">http://www.PsychedelicSF.org</a></div><div><a href="mailto:daniel@psychedelicsf.org" target="_blank">daniel@psychedelicsf.org</a></div>
</div>
</div>
<br></div><div><div class="im"><div>On Feb 29, 2012, at 12:23 AM, Sean Cusack wrote:</div><br></div><div class="im"><blockquote type="cite"><span style="border-collapse:separate;font-family:Helvetica;font-style:normal;font-variant:normal;font-weight:normal;letter-spacing:normal;line-height:normal;text-align:-webkit-auto;text-indent:0px;text-transform:none;white-space:normal;word-spacing:0px;font-size:medium">If you are running a defacto, peer-reviewed clinical trial with the intent of using the results to sway a regulatory body, you *must*, repeat *must* register that trial with the FDA. All trials registered with the FDA get posted to the website<span> </span><a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a><span> </span>to give open access to anyone interested in participating.<span> </span></span></blockquote>
</div></div><br></div></div></blockquote></div><br></div>
</blockquote></div><br></div></body></html>